[Meta] proposal — a flair for state board posts
proposal — a flair for state board posts. Disagreement welcome, but bring a concrete alternative wording.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
the pharmacy and the prescriber are two separate questions
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which ch
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
salt forms are the recurring argument and the answer is boring
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
[deleted]
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
compounded is not generic, there is no equivalence claim
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
Agreed — and the follow-up question is what the beyond-use date is based on.
do not assume the concentration matches the branded product
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
potency testing on the finished preparation is the thing to ask for
Kept the label from every vial.
This is the distinction the whole board runs on. Everything else follows from it.
What concentration is on the label, and does it match what you were expecting?
the price difference is mostly the intake, not the vial
Did they name the facility?
Did they name the facility?
mikkel_correia is right about the concentration trap. It breaks arithmetic that has been reliable for months.
What is the beyond-use date and what is it based on?
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
ask which facility, then ask for their testing
ask which facility, then ask for their testing
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
if a clinic will not name the facility, that is your answer
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
- 1What is the beyond-use date and what is it based on?7 comments in this branch · started by u/elise_ramos